Docetaxel in prostate cancer.

  title={Docetaxel in prostate cancer.},
  author={Eric Jay Small},
  journal={Anti-cancer drugs},
  volume={12 Suppl 1},
In contrast to several other tumor types, there has been relatively little experience with docetaxel in hormone-refractory prostate cancer. However, two phase II trials investigated the combination of docetaxel with estramustine, and reported prostate-specific antigen response rates of 69 and 74% and objective responses in 23% and 57% of patients. This activity is comparable with that of other estramustine combinations. However, there is uncertainty about whether estramustine itself should be… CONTINUE READING